---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-022398"
form_type: "8-K"
ticker: "PMI"
cik: "0002030617"
company_name: "Picard Medical, Inc."
filed_at: "2026-07-02T12:15:19+00:00"
generated_at: "2026-07-02T12:20:11.968697+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Picard Medical reports 85% YoY revenue growth, gross margin improvement to 28% in pre-annual meeting presentation

## Summary
- Revenue increased 85% YoY; US revenue up 116%; gross margin improved to 28% from year-end 2025.
- Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
- Annual meeting on July 17, 2026; proposals include director elections, capital structure amendments, auditor ratification, exec comp advisory vote.
- Interim CEO Richard Fang highlights business progress despite recent leadership changes.

## SEC filing metadata
- accession: 0001437749-26-022398
- form_type: 8-K
- ticker: PMI
- cik: 0002030617
- company_name: Picard Medical, Inc.
- filed_at: 2026-07-02T12:15:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/0001437749-26-022398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/pmi20251008_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-022398
- JSON: https://secwatch.observer/filing/0001437749-26-022398.json
- Plain text: https://secwatch.observer/filing/0001437749-26-022398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.